Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Inhibrx Biosciences, Inc.

INBX · Nasdaq · CIK 0002007919 · Healthcare · Biotechnology

INSIDER SIGNAL

75.0 / 100

3 buyers · 19 purchase transaction lines · $6.3M gross purchase

WHY THIS SIGNAL?

Buyer breadthModerate
Purchase sizeStrong
RoleModerate
RecencyStrong
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+21.0 / 35
Purchase size+22.1 / 25
Role+13.0 / 20
Recency+9.4 / 10
Conviction+9.6 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)
  • ✓ Recent activity · latest purchase 2026-10-14

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
MANHARD KIMBERLYDirector
▼▼▼▼▼
Lappe MarkChief Executive Officer
●●●●
Kayyem Jon FaizDirector
●●●
FORSYTH DOUGLASDirector
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS3
PURCHASE CONCENTRATION71%Largest buyer: Lappe Mark · $4.5M
CLUSTER BUYING · 15D3 insidersPeak activity: 2026-09-08–2026-09-23

Roles in the peak window: Chief Executive Officer, Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

75.0 / 100

Latest recorded score

↓ -0.4 ptsversus the previous recorded snapshot
  1. 73.2
  2. 73.1
  3. 75.5
  4. 75.4
  5. 75.0

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

19Purchases
5Sales
0Other Form 4 lines
9SEC filings · 365 days
BUYING19 qualifying P line(s) · 180 days
SELLING5 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-14.2%
3M
+6.8%
6M
+1.8%
12M
+149.9%

Volatility & liquidity

Volatility
99.9%
Beta
3.67
Avg daily value
USD 27.6M

Valuation

Market cap
USD 1.3B
P/E
—

Fundamentals

Profit margin
0.0%
ROE
-1752.2%
Industry
Biotechnology

Market data

Price data up to: 2026-10-18 · Price source: OpenBB/yfinance · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-07 · From Yahoo Finance: Profit margin · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
3,432,642
Previous report
3,393,511
Avg daily volume
290,359
Days to cover
11.8

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-14Lappe MarkPurchase (P)Common Stock9,940USD 84.55USD 840,401SEC filing ↗
2026-09-28Lappe MarkPurchase (P)Common Stock4,500USD 100.76USD 453,420SEC filing ↗
2026-09-25Lappe MarkPurchase (P)Common Stock5,500USD 99.16USD 545,373SEC filing ↗
2026-09-23Kayyem Jon FaizPurchase (P)Common Stock5,000USD 100.00USD 500,000SEC filing ↗
2026-09-16Kayyem Jon FaizPurchase (P)Common Stock5,000USD 100.00USD 500,000SEC filing ↗
2026-09-08Lappe MarkPurchase (P)Common Stock25,000USD 105.81USD 2,645,358SEC filing ↗
2026-09-08Kayyem Jon FaizPurchase (P)Common Stock5,000USD 113.52USD 567,600SEC filing ↗
2026-09-08FORSYTH DOUGLASPurchase (P)Common Stock2,500USD 114.65USD 286,625SEC filing ↗
2024-11-20Kayyem Jon FaizPurchase (P)Common Stock18,750USD 14.19USD 266,062SEC filing ↗
2024-11-19Kayyem Jon FaizPurchase (P)Common Stock34,843USD 14.23USD 495,816SEC filing ↗
2024-10-03Vuori Kristiina MDPurchase (P)Common Stock6,667USD 15.00USD 100,005SEC filing ↗
2024-09-16Lappe MarkPurchase (P)Common Stock13,037USD 17.13USD 223,324SEC filing ↗
2024-09-12Lappe MarkPurchase (P)Common Stock26,963USD 15.05USD 405,793SEC filing ↗
2024-09-11Vuori Kristiina MDPurchase (P)Common Stock6,457USD 15.07USD 97,307SEC filing ↗
2024-09-10Vuori Kristiina MDPurchase (P)Common Stock179USD 15.00USD 2,685SEC filing ↗

Form 4 evidence

24 transaction lines in the latest 365-day window; 69 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-14Lappe MarkPurchase (P)Common Stock9,940USD 84.55USD 840,401SEC filing ↗
2026-09-28Lappe MarkPurchase (P)Common Stock4,500USD 100.76USD 453,420SEC filing ↗
2026-09-25Lappe MarkPurchase (P)Common Stock5,500USD 99.16USD 545,373SEC filing ↗
Show recent Form 4 evidence (13 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-14Lappe MarkPurchase (P)Common Stock9,940USD 84.55USD 840,401SEC filing ↗
2026-09-28Lappe MarkPurchase (P)Common Stock4,500USD 100.76USD 453,420SEC filing ↗
2026-09-25Lappe MarkPurchase (P)Common Stock5,500USD 99.16USD 545,373SEC filing ↗
2026-09-23Kayyem Jon FaizPurchase (P)Common Stock5,000USD 100.00USD 500,000SEC filing ↗
2026-09-16Kayyem Jon FaizPurchase (P)Common Stock5,000USD 100.00USD 500,000SEC filing ↗
2026-09-15MANHARD KIMBERLYSale (S)Common Stock500USD 105.05USD 52,525SEC filing ↗
2026-09-14MANHARD KIMBERLYSale (S)Common Stock500USD 110.26USD 55,130SEC filing ↗
2026-09-11MANHARD KIMBERLYSale (S)Common Stock500USD 111.78USD 55,890SEC filing ↗
2026-09-09MANHARD KIMBERLYSale (S)Common Stock500USD 115.80USD 57,900SEC filing ↗
2026-09-08MANHARD KIMBERLYSale (S)Common Stock500USD 115.14USD 57,570SEC filing ↗
2026-09-08Lappe MarkPurchase (P)Common Stock25,000USD 105.81USD 2,645,358SEC filing ↗
2026-09-08Kayyem Jon FaizPurchase (P)Common Stock5,000USD 113.52USD 567,600SEC filing ↗
2026-09-08FORSYTH DOUGLASPurchase (P)Common Stock2,500USD 114.65USD 286,625SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerINBX
CIK0002007919
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history69 transaction lines from 2024-05-29 to 2026-10-14
46 P purchase lines · 8 S sale lines · 15 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.